Referred to the House Committee on Ways and Means.
The bill adds a new Internal Revenue Code section that disallows federal tax deductions for direct-to-consumer advertising expenses for covered prescription drugs and certain compounded drugs. "Direct-to-consumer advertising" covers broadcast, mail, billboards, internet and digital platforms but excludes journal and periodical publications. The rule applies to sponsors of prescription drug products and owners of outsourcing facilities and takes effect for amounts paid or incurred after enactment.
Role of tax code: public health tool versus penalty on speech
Relative to its intended legislative type, this bill is a clear and direct substantive tax law amendment that establishes a single, specific prohibition (denial of deductions for direct-to-consumer advertising of defined drugs) and supplies several key definitions and an effective date.
The bill adds a new Internal Revenue Code section that disallows federal tax deductions for direct-to-consumer advertising expenses for covered prescription drugs and certain compounded drugs. "Direct-to-consumer advertising" covers broadcast, mail, billboards, internet and digital platforms but excludes journal and periodical publications.
The rule applies to sponsors of prescription drug products and owners of outsourcing facilities and takes effect for amounts paid or incurred after enactment.
The change increases taxable income for firms engaging in such consumer-facing drug advertising by denying a deduction for those expenses.
Narrow but politically sensitive measure lacking broad compromise, likely to draw intense industry opposition and possible litigation.
Relative to its intended legislative type, this bill is a clear and direct substantive tax law amendment that establishes a single, specific prohibition (denial of deductions for direct-to-consumer advertising of defined drugs) and supplies several key definitions and an effective date. It lacks ancillary procedural and anti-avoidance detail that would commonly accompany a broad tax-policy prohibition.
Role of tax code: public health tool versus penalty on speech
These are examples from the analysis, not a ranked list of the most-affected groups.
Role of tax code: public health tool versus penalty on speech
Likely supportive because it curbs pharmaceutical industry incentives to promote drugs directly to consumers and reduces implicit taxpayer subsidies.
Views the policy as aligning private incentives with public health goals by removing a tax break for persuasive consumer advertising.
Concerns would focus on ensuring patients still receive unbiased treatment information.
Cautious support possible if the bill is narrowly targeted and administrable.
Sees merit in discouraging aggressive consumer marketing, but worries about administrative complexity, unintended market effects, and constitutional challenges.
Would want revenue estimates and regulatory guidance before full endorsement.
Likely opposed as an overreach that effectively penalizes commercial speech and expands tax burdens on pharmaceutical companies.
Views this as government interference in market communications that could harm innovation, job creation, and consumer information.
Prefers market-based or state-level solutions instead.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow but politically sensitive measure lacking broad compromise, likely to draw intense industry opposition and possible litigation.
The bill has not accumulated any surfaced votes yet.
Role of tax code: public health tool versus penalty on speech
Narrow but politically sensitive measure lacking broad compromise, likely to draw intense industry opposition and possible litigation.
Relative to its intended legislative type, this bill is a clear and direct substantive tax law amendment that establishes a single, specific prohibition (denial of deductions for direct-to-consumer advertising of define…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.